The ESG Weekly: The ESG of vaccines, and shareholders say JPM must talk climate
There are some promising COVID\u201019 vaccines in early human trails, but we have some questions if they are successful: Who will own the patent? Who will distribute them? Who will be responsible if something goes wrong? And then we discuss the recent proxy battle at JPMorgan that ended with some interesting wins for climate activists.